Esbriet is owned by Genentech Inc.

Esbriet contains Pirfenidone.

Esbriet has a total of 21 drug patents out of which 1 drug patent has expired.

Expired drug patents of Esbriet are:

• US9561217

Esbriet was authorised for market use on 11 January, 2017.

Esbriet is available in tablet;oral dosage forms.

Esbriet can be used as pirfenidone dose escalation regimen for treatment of ipf as 801 mg/day for days 1-7 of the regimen, 1602 mg/day for days 8-14 of the regimen, and 2403 mg/day for at least day 15 of the regimen, discontinuing smoking to avoid reduced pirfenidone efficacy and then administering pirfenidone; discontinuing administration of a strong cyp1a2 inducer to avoid reduced pirfenidone efficacy and then administering pirfenidone, method of administering pirfenidone capsules to treat a fibrotic condition, continued dosing or dosage modification following elvated liver enzymes in use of pirfenidone, continued dosing or dosage modification following elevated liver enzymes in treatment of idiopathic pulmonary fibrosis, discontinuing administration of fluvoxamine to avoid drug interactions with pirfenidone and then administering pirfenidone; administering pirfenidone while avoiding co-administration of fluvoxamine to avoid drug interactions with pirfenidone, pirfenidone dose escalation regimen for treatment of fibrosis as 801 mg/day for days 1-7 of the regimen, 1602 mg/day for days 8-14 of the regimen, and 2403 mg/day for at least day 15 of the regimen, administering pirfenidone while avoiding concomitant use of a cyp1a2 inhibitor that is a moderate to strong inhibitor of both cyp1a2 and another cyp enzyme selected from cyp2c9, cyp2c19, and cyp2d6; discontinuing use of a cyp1a2 inhibitor that is a moderate to strong inhibitor of both cyp1a2 and another cyp enzyme selected from cyp2c9, cyp2c19, and cyp2d6 and then administering pirfenidone, method for administering pirfenidone to avoid reduced efficacy by discontinuing smoking or by discontinuing or avoiding another strong cyp1a2 inducer, method for administering pirfenidone to reduce drug interactions with fluvoxamine, dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by discontinuing pirfenidone until biomarkers are within normal limits, followed by 801 mg/day, dose, then 1602 mg/day in treatment of ipf; full daily dosing following grade 2 abnormality in liver function biomarker after pirfenidone administration in treatment of ipf; dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by discontinuing pirfenidone until biomarkers are within normal limits, followed by administering full daily dose in treatment of ipf; dosing 1602 mg/day pirfenidone following grade 2 abnormality in liver function biomarker after pirfenidone administration in treatment of ipf; dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by discontinuing pirfenidone until biomarkers are within normal limits followed by administering 1602 mg/day in treatment of ipf; dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by administering 801 mg/day followed by administering 1602 mg/day in treatment of ipf, method of administering a granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone as recited in claim 1, to treat idiopathic pulmonary fibrosis, dosage modification in treatment with pirfenidone to reduce drug interactions with ciprofloxacin, administering pirfenidone while avoiding co-administration of a strong cyp1a2 inhibitor to avoid drug interactions with pirfenidone; discontinuing administration of a strong cyp1a2 inhibitor to avoid drug interactions with pirfenidone and then administering pirfenidone, dose escalation over 14 days for treatment of idiopathic pulmonary fibrosis, method for administering pirfenidone to avoid reduced efficacy by avoiding smoking or by avoiding another strong cyp1a2 inducer, dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by discontinuing pirfenidone until biomarkers are within limits, then sub-2400mg/day dose, then full daily dose in treatment of ipf; dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by administering sub-2400mg/day dose then full daily dose in treatment of ipf; dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by administering sub-2400 mg/day dose then full day daily dose in treatment of ipf; dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by discontinuing pirfenidone until biomarkers are within normal limits, then sub-2400mg/day dose, then full daily dose in treatment of ipf.

The generics of Esbriet are possible to be released after 28 March, 2037.